KPIs & Operating Metrics(New)

Balance Sheet

Cash Flow Statement

Acquisitions Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Divestments Dividends Paid - Common Dividends Paid - Common Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased Short-Term Debt issuances

Daily Values

Growth Metrics

Bristol Myers Squibb (BMY) Divestments (2016 - 2026)

Bristol Myers Squibb has reported Divestments over the past 18 years, most recently at $312.0 million for Q1 2026.

Quarterly Divestments rose 28.4% to $312.0 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $1.1 billion through Mar 2026, up 3.54% year-over-year, with the annual reading at $1.1 billion for FY2025, 2.55% down from the prior year.
Divestments was $312.0 million for Q1 2026 at Bristol Myers Squibb, up from $279.0 million in the prior quarter.
Over five years, Divestments peaked at $490.0 million in Q4 2022 and troughed at $192.0 million in Q2 2022.
The 5-year median for Divestments is $255.0 million (2024), against an average of $276.2 million.
Year-over-year, Divestments soared 175.28% in 2022 and then tumbled 50.82% in 2023.
A 5-year view of Divestments shows it stood at $490.0 million in 2022, then tumbled by 50.82% to $241.0 million in 2023, then skyrocketed by 38.17% to $333.0 million in 2024, then dropped by 16.22% to $279.0 million in 2025, then grew by 11.83% to $312.0 million in 2026.
Per Business Quant, the three most recent readings for BMY's Divestments are $312.0 million (Q1 2026), $279.0 million (Q4 2025), and $279.0 million (Q3 2025).